BET inhibitor

DRUG CLASS:

BET inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

MYC expression	Diffuse Large B Cell Lymphoma	MYC expression	Diffuse Large B Cell Lymphoma	RG6146 Sensitive: C2 – Inclusion Criteria RG6146 Sensitive : C2	RG6146 Sensitive: C2 – Inclusion Criteria RG6146 Sensitive : C2
MAF overexpression	Multiple Myeloma	MAF overexpression	Multiple Myeloma	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3
EPCAM expression	Triple Negative Breast Cancer	EPCAM expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
SOX9 expression	Triple Negative Breast Cancer	SOX9 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
GJA1 expression	Triple Negative Breast Cancer	GJA1 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
CD24 expression	Triple Negative Breast Cancer	CD24 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
MYC expression + MYC rearrangement	Lymphoma	MYC expression + MYC rearrangement	Lymphoma	BET inhibitor Sensitive: C3 – Early Trials BET inhibitor Sensitive : C3	BET inhibitor Sensitive: C3 – Early Trials BET inhibitor Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	GSK525762 Sensitive: C3 – Early Trials GSK525762 Sensitive : C3	GSK525762 Sensitive: C3 – Early Trials GSK525762 Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
BRD4 overexpression	Retinoblastoma	BRD4 overexpression	Retinoblastoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	talazoparib + GSK525762 Sensitive: D – Preclinical talazoparib + GSK525762 Sensitive : D	talazoparib + GSK525762 Sensitive: D – Preclinical talazoparib + GSK525762 Sensitive : D
FLT3-ITD mutation + FLT3 D835	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 D835	Acute Myelogenous Leukemia	DAK539 Sensitive: D – Preclinical DAK539 Sensitive : D	DAK539 Sensitive: D – Preclinical DAK539 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	DAK539 Sensitive: D – Preclinical DAK539 Sensitive : D	DAK539 Sensitive: D – Preclinical DAK539 Sensitive : D
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
HER-2 positive	Estrogen Receptor Positive Breast Cancer	HER-2 positive	Estrogen Receptor Positive Breast Cancer	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D
HUWE1 mutation	Cervical Cancer	HUWE1 mutation	Cervical Cancer	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D
MYC overexpression	Cervical Cancer	MYC overexpression	Cervical Cancer	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D
P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYC expression	Multiple Myeloma	MYC expression	Multiple Myeloma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D
KRAS Q61K	Non Small Cell Lung Cancer	KRAS Q61K	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D

BET inhibitor

BET inhibitor

Associations(69)

Associations
(69)